15,000 second chances: Bone Marrow Transplant program celebrates new milestone

April 24, 2019 | Michael Easterling and Samantha Bonar

City of Hope’s bone marrow transplant program recently performed the procedure on its 15,000th patient, a remarkable milestone considering that the initiative started with just two physicians, three beds and guarded expectations in 1976.

Continue Reading

City of Hope awarded $7.5M to develop treatment for rare cancer

April 3, 2019 | Zen Vuong

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.

Solving the mystery of cutaneous lymphoma

September 30, 2018 | Abe Rosenberg

City of Hope dermatologist Christiane Querfeld, M.D., Ph.D., and her team may have uncovered the underlying cause of a stubborn form of lymphoma

Surprising Diagnosis Leads Skin Cancer Patient to City of Hope

May 29, 2018 | Robert Young

Barbara Dorfman ran a large nursery school for 25 years, helped raise five children and has enjoyed an exceptionally active lifestyle with her husband, but nothing could prepare her for the diagnosis she received four years ago.

Patient with Rare Skin Cancer Grateful for City of Hope Dermatology Team

May 22, 2018 | Robert Young

When what he thought was just a rash on his forehead spread to his face and neck, Joshua Singer sought medical help. After a number of treatments failed to figure out the problem, he turned to City of Hope, and renowned dermatologist Christiane Querfeld. M.D., Ph.D.

10 things you should know about cutaneous T cell lymphoma

June 29, 2016 | City of Hope

Cutaneous T cell lymphoma (CTCL), a type of non-Hodgkin lymphoma that originates in the skin, shouldn’t be confused with skin cancer. Because it’s rare and difficult to understand, City of Hope put together this list of important information you might not know about CTCL.

Cutaneous T cell lymphoma Q&A: Treatment, misdiagnosis, and advances in research

May 23, 2016 | City of Hope

Jasmine M. Zain, M.D., director of the T cell Lymphoma Program, discusses various Cutaneous T cell lymphoma (CTCL) treatment options, the challenges facing minorities and promising research on the horizon.